www.idosr.org
©IDOSR PUBLICATIONS
Mukisa
ISSN: 2550-794X
International Digital Organization for Scientific Research
IDOSR JOURNAL OF SCIENTIFIC RESEARCH 10(2):112-118, 2025.
https://doi.org/10.59298/IDOSRJSR/2024/10.2.112118
IDOSRJSR10.200000

Nanoparticle Based Gene Therapy for Obesity and Metabolic Syndrome

Mukisa Ian Mugaiga

Department of Pharmacology Kampala International University Uganda
Email:mugaiga.mukisa@studwc.kiu.ac.ug

ABSTRACT

Obesity and metabolic syndrome are multifactorial conditions characterized by dysregulated energy metabolism, insulin resistance, chronic inflammation, and increased risk of diabetes and cardiovascular disease. Conventional pharmacological treatments often provide modest benefits and suffer from limited durability. Gene therapy has emerged as a transformative approach to correct the underlying molecular defects driving these disorders. However, effective delivery of genetic material such as DNA, mRNA, siRNA, and miRNA which remains a formidable challenge due to degradation, poor cellular uptake, and off-target effects. Nanoparticles offer versatile delivery platforms that protect genetic cargo, improve biodistribution, and enable tissue-specific targeting. Recent studies demonstrate that nanoparticle-based gene therapy can modulate pathways such as adipogenesis, lipolysis, insulin signaling, and appetite regulation, producing sustained metabolic improvements in preclinical models. This review explores the principles of nanoparticle-mediated gene therapy, recent advances in obesity and metabolic syndrome research, translational barriers, clinical perspectives, and future directions. Nanoparticle-enabled gene therapy holds immense potential, but long-term safety, large-scale production, and regulatory approval remain significant hurdles before clinical application.

Keywords: Obesity, Metabolic syndrome, Gene therapy, Nanoparticles, Nucleic acids

INTRODUCTION

Obesity has become one of the most prevalent chronic conditions globally, affecting more than one billion people[1–3]. It is characterized by excessive accumulation of adipose tissue, accompanied by metabolic disturbances that predispose individuals to type 2 diabetes mellitus, dyslipidemia, hypertension, non-alcoholic fatty liver disease, and cardiovascular disease. Collectively, these interrelated conditions constitute metabolic syndrome, a major risk factor for morbidity and mortality worldwide[4–6]. The pathogenesis of obesity and metabolic syndrome is complex, involving genetic predisposition, environmental influences, sedentary lifestyle, and dietary patterns. Importantly, molecular mechanisms underpinning these disorders include dysregulation of adipogenesis, impaired insulin signaling, chronic low-grade inflammation, mitochondrial dysfunction, and altered neuroendocrine regulation of appetite and satiety[7, 8].

Current management strategies focus on lifestyle modifications, pharmacological therapies, and bariatric surgery. Although effective in some cases, these approaches have major limitations. Lifestyle interventions often fail due to low long-term adherence, while bariatric surgery is invasive, costly, and associated with complications. Pharmacological agents such as orlistat, GLP-1 receptor agonists, and phentermine-topiramate induce moderate weight loss but rarely sustain long-term metabolic correction[9, 10]. Moreover, these therapies typically address symptoms rather than the root molecular causes of obesity and metabolic syndrome. This therapeutic gap has motivated interest in gene therapy as a means of directly modulating pathogenic pathways.

Gene therapy encompasses the introduction, modification, or suppression of genetic material to influence cellular function and restore metabolic balance [11, 12]. In the context of obesity, gene therapy can target pathways regulating energy expenditure, appetite, adipocyte differentiation, lipid metabolism, and insulin sensitivity. For example, siRNA can silence genes promoting lipogenesis, while miRNA therapy can restore regulatory networks disrupted in obesity. DNA and mRNA delivery can enhance expression of beneficial proteins such as adiponectin, leptin, or mitochondrial enzymes that increase thermogenesis. These strategies hold promise for addressing the underlying drivers of metabolic dysfunction rather than merely alleviating symptoms[13].

A major challenge in gene therapy, however, is the efficient and safe delivery of nucleic acids. Naked DNA or RNA is highly susceptible to enzymatic degradation, exhibits poor cellular uptake, and may trigger immune

responses. Viral vectors, such as adenoviruses and lentiviruses, have been employed in early gene therapy studies but raise safety concerns due to immunogenicity and insertional mutagenesis. Non-viral delivery systems, particularly nanoparticles, provide an attractive alternative. Nanoparticles protect genetic cargo from degradation, facilitate cellular internalization, and can be engineered for tissue-specific targeting. They also allow controlled release and reduced immunogenicity compared to viral vectors [14–17].

Nanoparticles used in gene therapy include lipid nanoparticles (LNPs), polymeric nanoparticles, dendrimers, and inorganic systems such as gold and silica nanoparticles. LNPs have gained particular prominence following their successful use in mRNA vaccines, demonstrating scalability and clinical safety. Polymeric nanoparticles such as those made from PLGA or chitosan offer biodegradability and tunable release properties[18]. Functionalization with ligands such as peptides, antibodies, or aptamers enables active targeting of tissues such as adipose depots, liver, or skeletal muscle. This is highly relevant in obesity, where targeting metabolically active tissues is essential for therapeutic efficacy[19–21].

In obesity and metabolic syndrome research, nanoparticle-based gene therapy has been explored for multiple strategies: silencing of adipogenic transcription factors (e.g., PPARγ, C/EBPα), enhancing energy expenditure via expression of uncoupling proteins, modulating appetite regulators such as leptin or neuropeptide Y, and restoring insulin sensitivity through modulation of IRS1, GLUT4, or AMPK pathways[5, 22]. Preclinical studies in animal models have shown significant improvements in weight control, glucose homeostasis, lipid metabolism, and inflammatory status.

Despite these encouraging findings, translation to clinical practice remains at an early stage. Major barriers include ensuring long-term safety, avoiding off-target effects, optimizing dosage, scaling up manufacturing, and navigating complex regulatory frameworks. Furthermore, obesity is a multifactorial disease, and heterogeneity among patients requires tailored therapeutic approaches. Nonetheless, the convergence of nanotechnology and gene therapy provides a promising avenue to achieve durable metabolic correction in obesity and metabolic syndrome [23]. This review provides a comprehensive discussion of nanoparticle-based gene therapy for obesity. Section 2 outlines the principles and design of nanoparticle gene delivery systems. Section 3 highlights recent advances in preclinical and emerging clinical studies. Section 4 discusses translational barriers. Section 5 examines clinical perspectives. Section 6 looks ahead to future directions, including precision nanomedicine and integration with digital health technologies.

2. Principles of Nanoparticle Gene Delivery Systems

Nanoparticle-based systems are designed to overcome the intrinsic barriers of gene therapy. The fundamental principle involves encapsulating, condensing, or binding nucleic acids within nanocarriers to protect them from degradation and ensure delivery to target cells. The most widely studied categories include lipid nanoparticles, polymeric nanoparticles, dendrimers, and inorganic nanoparticles.

Lipid nanoparticles (LNPs) have gained global recognition following their role in mRNA COVID-19 vaccines. Their structure typically includes ionizable lipids, cholesterol, phospholipids, and polyethylene glycol (PEG)-lipid conjugates[18, 19, 24–26]. These components enable encapsulation of negatively charged nucleic acids and promote fusion with cell membranes for efficient cytoplasmic delivery. LNPs are especially relevant for obesity therapies that require delivery to hepatocytes or adipocytes, as they exhibit favorable biodistribution in these tissues.

Polymeric nanoparticles are formed from biodegradable polymers such as polyethylenimine (PEI), polylactic-co-glycolic acid (PLGA), and chitosan. PEI is highly efficient at condensing nucleic acids but can be cytotoxic; thus, modified versions are used to improve safety. PLGA nanoparticles provide sustained release and excellent biocompatibility, while chitosan-based systems are particularly attractive for oral delivery of gene therapies, which could improve patient compliance in chronic conditions like obesity[27–29].

Dendrimers are highly branched, tree-like macromolecules with a central core and multiple terminal groups that can be functionalized with drugs, nucleic acids, or targeting ligands. Their multivalency allows for high nucleic acid loading capacity and precise surface modifications. This makes them promising for multi-gene or combination therapies targeting the diverse pathways implicated in metabolic syndrome[30–32].

Inorganic nanoparticles such as gold, silica, and magnetic nanoparticles offer unique optical and magnetic properties that can be exploited for both delivery and imaging. Gold nanoparticles, for example, allow photothermal control of release, while magnetic nanoparticles can be guided to specific tissues using external magnetic fields. However, their long-term biocompatibility remains under investigation[6, 33].

Surface functionalization is a critical aspect of nanoparticle design. By conjugating targeting ligands such as peptides, antibodies, or aptamers, nanoparticles can selectively bind to receptors on adipocytes, hepatocytes, or hypothalamic neurons[19, 21, 34]. This active targeting improves efficacy while minimizing off-target effects. For example, nanoparticles functionalized with ligands targeting adipose vasculature have been shown to deliver siRNA specifically to fat tissue, silencing genes involved in lipogenesis.

Another important principle is stimuli-responsiveness. Smart nanoparticles can release their genetic cargo in response to physiological triggers such as pH, redox state, or enzymatic activity[35]. For instance, nanoparticles responsive to acidic environments may release genes selectively in endosomes after cellular uptake. This ensures that nucleic acids reach their intended intracellular site of action, such as the cytoplasm for mRNA or the nucleus for DNA.

Overall, the design of nanoparticle gene delivery systems integrates considerations of biocompatibility, stability, targeting, and release kinetics. These principles provide the foundation for applying gene therapy to obesity and metabolic syndrome.

3. Advances in Preclinical and Emerging Clinical Studies

Preclinical research has provided strong evidence supporting the potential of nanoparticle-mediated gene therapy in obesity and metabolic syndrome. Several strategies have been employed to modulate key molecular pathways involved in energy balance, lipid metabolism, and insulin sensitivity.

One major focus has been the use of siRNA and miRNA delivery. Silencing transcription factors such as PPARγ and C/EBPα, which drive adipogenesis, has been achieved using lipid and polymeric nanoparticles[36]. These interventions reduce adipocyte differentiation and fat accumulation in animal models. Similarly, siRNA targeting fatty acid synthase (FASN) or acetyl-CoA carboxylase has led to decreased lipogenesis and improved lipid profiles. miRNA delivery has also been explored, with miR-122 modulation in the liver showing significant improvements in cholesterol and triglyceride levels[37, 38].

Another promising avenue involves enhancing energy expenditure and thermogenesis. Nanoparticle delivery of genes encoding uncoupling proteins (UCP1, UCP3) or transcriptional regulators such as PRDM16 has been shown to stimulate browning of white adipose tissue and increase mitochondrial activity. These effects lead to sustained weight loss and improved glucose tolerance in preclinical studies[39, 40].

Appetite regulation is also a target. Leptin gene delivery using nanoparticles has demonstrated restoration of leptin sensitivity in obese models, overcoming resistance that commonly develops with exogenous leptin administration[41, 42]. Nanoparticle-mediated delivery of neuropeptide Y antagonists has reduced food intake and improved metabolic parameters.

Insulin sensitivity and glucose metabolism have been addressed through nanoparticle-based delivery of genes enhancing GLUT4 expression or activating AMPK pathways. Such strategies improve glucose uptake in muscle and adipose tissues, reduce hepatic gluconeogenesis, and restore systemic insulin responsiveness[43].

Emerging clinical studies, while limited, highlight the translational potential. Early-phase trials with lipid nanoparticles carrying siRNA targeting hepatic genes involved in cholesterol metabolism (e.g., PCSK9) have demonstrated safety and efficacy in lowering LDL cholesterol. While not obesity-specific, these successes provide a proof-of-concept for applying similar approaches to obesity-related pathways. Pilot studies with nanoparticle-based leptin therapy have also been initiated, though long-term results are awaited[44].

These advances highlight the versatility of nanoparticles in delivering diverse genetic materials and modulating multiple obesity-related pathways. Although still in the preclinical or early clinical phase, these findings establish a strong foundation for translation.

4. Translational Barriers

Despite promising preclinical evidence, several barriers hinder clinical translation of nanoparticle-based gene therapy for obesity. Safety remains the foremost concern. Nanoparticles may accumulate in the liver, spleen, or kidneys, raising the risk of long-term toxicity. Immune activation is another risk, particularly with repeated dosing of lipid or polymeric nanoparticles. Ensuring that nucleic acid cargo is expressed only in target tissues is critical to avoid off-target effects.

Manufacturing challenges are significant. Producing nanoparticles with uniform size, charge, and loading efficiency on a commercial scale requires sophisticated equipment and stringent quality control. Batch-to-batch variability can compromise reproducibility, which is a major barrier to regulatory approval[45].

Regulatory complexity is also considerable. Nanoparticle-based gene therapies sit at the intersection of biologics, drugs, and devices, requiring comprehensive evaluation of safety, pharmacokinetics, biodistribution, and immunogenicity. Regulatory agencies demand long-term safety data, particularly since obesity therapies may require chronic or repeated administration[46].

Patient heterogeneity presents another challenge. Obesity and metabolic syndrome are influenced by genetics, environment, microbiota, and lifestyle, leading to variability in treatment response. A one-size-fits-all gene therapy is unlikely to succeed, necessitating personalized approaches[47].

Finally, economic considerations are substantial. Developing and manufacturing nanoparticle gene therapies is costly, and without strategies to reduce expenses, these treatments may remain inaccessible to much of the global population[48].

Overcoming these barriers requires multidisciplinary collaboration between nanotechnologists, clinicians, pharmacologists, and regulatory bodies. Advances in scalable manufacturing, rigorous safety studies, and adaptive trial designs will be critical to move the field forward.

5. Clinical Perspectives

Although nanoparticle-based gene therapy for obesity is still at an early stage, clinical perspectives are promising. The success of lipid nanoparticles in delivering mRNA vaccines has validated the safety, scalability, and efficacy of this platform in humans, providing confidence in its application for metabolic diseases[49].

In obesity management, nanoparticle-based gene therapies could complement existing pharmacological approaches. For example, combining GLP-1 receptor agonists with nanoparticle-delivered siRNA targeting lipogenesis could provide synergistic effects. Similarly, nanoparticles delivering appetite-regulating genes may enhance the durability of lifestyle interventions or bariatric surgery outcomes[50].

Pilot clinical studies in related fields offer encouraging insights. siRNA therapies targeting PCSK9 have already reached the market for hypercholesterolemia, demonstrating the feasibility of long-term gene silencing using nanoparticles. Translating such successes to obesity requires identification of appropriate molecular targets and rigorous clinical trial validation[50].

Patient acceptance will depend on demonstrating safety, durability of effect, and affordability. Since obesity therapies are typically long-term, regulatory agencies will require robust chronic safety data. Ethical considerations, including equitable access and avoidance of genetic manipulation stigma, must also be addressed[51].

Clinically, nanoparticle-based gene therapy holds the potential to shift obesity treatment from symptomatic management to durable molecular correction. If proven safe and effective, it could offer a paradigm shift in how metabolic diseases are treated[51].

6. Future Directions

Future progress in nanoparticle-based gene therapy for obesity and metabolic syndrome will depend on several key directions. Precision medicine will be central, tailoring therapies to individual genetic, metabolic, and microbiome profiles. Advances in genomics and metabolomics will enable patient stratification and identification of optimal molecular targets.

Artificial intelligence and computational modeling will play a growing role in designing nanoparticles with optimal pharmacokinetics and biodistribution. Predictive algorithms can accelerate formulation development and reduce reliance on trial-and-error experimentation.

Stimuli-responsive and hybrid nanoparticles are expected to gain importance. Carriers that release nucleic acids in response to pH, redox conditions, or enzymatic activity will improve targeting and reduce side effects. Hybrid systems combining gene therapy with conventional drugs in a single nanoparticle could provide multifaceted interventions against obesity.

Non-invasive delivery routes such as oral, inhalable, or transdermal nanoparticle systems could improve patient compliance, especially for chronic use. Chitosan-based oral nanoparticles, for example, are promising for delivering siRNA targeting gastrointestinal hormones involved in satiety regulation.

Integration with digital health platforms will further enhance the impact of gene therapy. Wearable devices coupled with nanosensor monitoring could provide real-time feedback on metabolic responses, enabling adaptive dosing strategies.

Ultimately, interdisciplinary collaboration will be essential. By bringing together expertise in nanotechnology, molecular biology, clinical medicine, and regulatory science, the field can overcome existing challenges and deliver safe, effective, and accessible nanoparticle-based gene therapies for obesity and metabolic syndrome.

CONCLUSION

Nanoparticle-based gene therapy offers a revolutionary approach to treating obesity and metabolic syndrome by addressing the underlying molecular mechanisms of these conditions. Preclinical studies demonstrate the ability to modulate adipogenesis, thermogenesis, appetite, and insulin sensitivity with promising results. Although significant barriers remain, including safety, manufacturing, and regulation, advances in nanoparticle design and precision medicine promise a future where gene therapy could provide durable and personalized solutions for obesity and its complications.

REFERENCES

1. Alanazi, A., Craven, A., Spirou, S.V., Santos-Martinez, M.J., Medina, C., Gobbo, O.L.: Nanomedicine as a Promising Treatment Approach for Obesity. J. Nanotheranostics. 6, 21 (2025). https://doi.org/10.3390/jnt6030021
2. Ejemot-Nwadiaro, R.I., Betiang, P.A., Basajja, M., Uti, D.E.: Obesity and Climate Change: A Two-way Street with Global Health Implications. Obes. Med. 56, 100623 (2025). https://doi.org/10.1016/j.obmed.2025.100623
3. Izah, S.C., Betiang, P.A., Paul-Chima Ugwu, O., Ainebyoona, C., Uti, D.E., Echegu, D.A., Alum, B.N.: The Ketogenic Diet in Obesity Management: Friend or Foe? Cell Biochem. Biophys. (2025). https://doi.org/10.1007/s12013-025-01878-0
4. Obasi, D.C., Abba, J.N., Aniokete, U.C., Okoroh, P.N., Akwari, A.Ak.: Evolving Paradigms in Nutrition Therapy for Diabetes: From Carbohydrate Counting to Precision Diets. Obes. Med. 100622 (2025). https://doi.org/10.1016/j.obmed.2025.100622
5. Umoru, G.U., Atangwho, I.J., David-Oku, E., Uti, D.E., De Campos, O.C., Udeozor, P.A., Nfona, S.O., Lawal, B., Alum, E.U.: Modulation of Lipogenesis by Tetracarpidium conophorum Nuts via SREBP-1/ACCA-1/FASN Inhibition in Monosodium-Glutamate-Induced Obesity in Rats. Nat. Prod. Commun. 20, 1934578X251344035 (2025). https://doi.org/10.1177/1934578X251344035
6. Uti, D.E., Omang, W.A., Alum, E.U., Ugwu, O.P.-C., Wokoma, M.A., Oplekwu, R.I., Atangwho, I.J., Egbung, G.E.: Combined Hyaluronic Acid Nanobioconjugates Impair CD44-Signaling for Effective Treatment Against Obesity: A Review of Comparison with Other Actors. Int. J. Nanomedicine. 20, 10101–10126 (2025). https://doi.org/10.2147/IJN.S529250
7. Bhardwaj, P., Au, C.C., Benito-Martin, A., Ladumor, H., Oshchepkova, S., Moges, R., Brown, K.A.: Estrogens and breast cancer: mechanisms involved in obesity-related development, growth and

progression. J. Steroid Biochem. Mol. Biol. 189, 161–170 (2019). https://doi.org/10.1016/j.jsbmb.2019.03.002
8. Alum, E.U.: Metabolic memory in obesity: Can early-life interventions reverse lifelong risks? Obes. Med. 55, 100610 (2025). https://doi.org/10.1016/j.obmed.2025.100610
9. Soliman, A.R., Magd eldin Saleem, H., El Meligi, A.A.H., Naguib, M., Sobh Mohamed, R., Abdelaziz, G.R., Rakha, M., Abdelghaffar, S., Hamed, A.E., Hammad, H.A.E.R. saeed, Mahmoud, E.O., Shaltout, I.: Metabolic/bariatric surgery optimization: a position statement by Arabic association for the study of diabetes and metabolism (AASD). Diabetol. Metab. Syndr. 17, 37 (2025). https://doi.org/10.1186/s13098-024-01564-w
10. Louis, M., Velazquez, E.: The Impact of New Weight-Loss Medications on Bariatric Surgery and Surgeon Employment. Cureus. 17, e83903. https://doi.org/10.7759/cureus.83903
11. Aja, P.M., Agu, P.C., Ogbu, C., Alum, E.U., Fasogbon, I.V., Musyoka, A.M., Ngwueche, W., Egwu, C.O., Tusubira, D., Ross, K.: RNA research for drug discovery: Recent advances and critical insight. Gene. 947, 149342 (2025). https://doi.org/10.1016/j.gene.2025.149342
12. Ikpozu, E.N., Offor, C.E., Igwenyi, I.O., Obaroh, I.O., Ibiam, U.A., Ukaidi, C.U.A.: RNA-based diagnostic innovations: A new frontier in diabetes diagnosis and management. Diab. Vasc. Dis. Res. 22, 14791641251334726 (2025). https://doi.org/10.1177/14791641251334726
13. Kloock, S., Ziegler, C.G., Dischinger, U.: Obesity and its comorbidities, current treatment options and future perspectives: Challenging bariatric surgery? Pharmacol. Ther. 251, 108549 (2023). https://doi.org/10.1016/j.pharmthera.2023.108549
14. Ge, H., Shi, Z., Liu, C., Lu, J., Yao, Y., Cheng, B.: Viral and non-viral vectors for gene therapy in the treatment of bone-related disorders: molecular insights and clinical perspectives. Mol. Aspects Med. 105, 101400 (2025). https://doi.org/10.1016/j.mam.2025.101400
15. Wang, C., Pan, C., Yong, H., Wang, F., Bo, T., Zhao, Y., Ma, B., He, W., Li, M.: Emerging non-viral vectors for gene delivery. J. Nanobiotechnology. 21, 272 (2023). https://doi.org/10.1186/s12951-023-02044-5
16. Wang, F., Liang, L., Wang, C., Zhang, C., Ye, Y., Dou, L., Shi, L., Zhou, D., Sun, X.: Non-Viral Gene Delivery Systems: Current Advances and Therapeutic Applications. Chem. – Asian J. n/a, e00684. https://doi.org/10.1002/asia.202500684
17. Estapé Senti, M., García del Valle, L., Schiffelers, R.M.: mRNA delivery systems for cancer immunotherapy: Lipid nanoparticles and beyond. Adv. Drug Deliv. Rev. 206, 115190 (2024). https://doi.org/10.1016/j.addr.2024.115190
18. Hald Albertsen, C., Kulkarni, J.A., Witzigmann, D., Lind, M., Petersson, K., Simonsen, J.B.: The role of lipid components in lipid nanoparticles for vaccines and gene therapy. Adv. Drug Deliv. Rev. 188, 114416 (2022). https://doi.org/10.1016/j.addr.2022.114416
19. Gui, K., Zhang, X., Chen, F., Ge, Z., Zhang, S., Qi, X., Sun, J., Yu, Z.: Lipid-polymer nanoparticles with CD133 aptamers for targeted delivery of all-trans retinoic acid to osteosarcoma initiating cells. Biomed. Pharmacother. Biomedecine Pharmacother. 111, 751–764 (2019). https://doi.org/10.1016/j.biopha.2018.11.118
20. Huang, X., Wan, J., Leng, D., Zhang, Y., Yang, S.: Dual-targeting nanomicelles with CD133 and CD44 aptamers for enhanced delivery of gefitinib to two populations of lung cancer-initiating cells. Exp. Ther. Med. 19, 192–204 (2020). https://doi.org/10.3892/etm.2019.8220
21. Kangarshahi, B.M., Naghib, S.M.: Nanogenosensors based on aptamers and peptides for bioelectrochemical cancer detection: an overview of recent advances in emerging materials and technologies. Discov. Appl. Sci. 6, 47 (2024). https://doi.org/10.1007/s42452-024-05681-z
22. Umoru, G.U., Atangwho, I.J., David-Oku, E., Uti, D.E., Agwupuye, E.I., Obeten, U.N., Maitra, S., Subramaniyan, V., Wong, L.S., Aljarba, N.H., Kumarasamy, V.: Tetracarpidium conophorum nuts (African walnuts) up-regulated adiponectin and PPAR-γ expressions with reciprocal suppression of TNF-α gene in obesity. J. Cell. Mol. Med. 28, e70086 (2024). https://doi.org/10.1111/jcmm.70086
23. Kakroodi, F.A., Khodadoust, E., Alizadeh, M., Hayaei Tehrani, R.S., Sarabi, P.A., Rahmanian, M., Vosough, M.: Current challenges and future directions of ATMPs in regenerative medicine. Regen. Ther. 30, 358–370 (2025). https://doi.org/10.1016/j.reth.2025.06.017
24. Aslam, R., Tiwari, V., Upadhyay, P., Tiwari, A.: REVOLUTIONIZING THERAPEUTIC DELIVERY: DIOSGENIN-LOADED SOLID LIPID NANOPARTICLES UNLEASH ADVANCED CARRIERS. Int. J. Appl. Pharm. 124–133 (2024). https://doi.org/10.22159/ijap.2024v16i1.49306
25. Borges, A., de Freitas, V., Mateus, N., Fernandes, I., Oliveira, J.: Solid Lipid Nanoparticles as Carriers of Natural Phenolic Compounds. Antioxidants. 9, 998 (2020). https://doi.org/10.3390/antiox9100998
26. Uti, D.E., Alum, E.U., Atangwho, I.J., Ugwu, O.P.-C., Egbung, G.E., Aja, P.M.: Lipid-based nano-carriers for the delivery of anti-obesity natural compounds: advances in targeted delivery and precision therapeutics. J. Nanobiotechnology. 23, 336 (2025). https://doi.org/10.1186/s12951-025-03412-z

27. Austria, E., Bilek, M., Varamini, P., Akhavan, B.: Breaking biological barriers: Engineering polymeric nanoparticles for cancer therapy. Nano Today. 60, 102552 (2025). https://doi.org/10.1016/j.nantod.2024.102552
28. Cavalcante de Freitas, P.G., Rodrigues Arruda, B., Araújo Mendes, M.G., Barroso de Freitas, J.V., da Silva, M.E., Sampaio, T.L., Petrilli, R., Eloy, J.O.: Resveratrol-Loaded Polymeric Nanoparticles: The Effects of D-α-Tocopheryl Polyethylene Glycol 1000 Succinate (TPGS) on Physicochemical and Biological Properties against Breast Cancer In Vitro and In Vivo. Cancers. 15, 2802 (2023). https://doi.org/10.3390/cancers15102802
29. Alum, E.U., Nwuruku, O.A., Ugwu, O.P.-C., Uti, D.E., Alum, B.N., Edwin, N.: Harnessing nature: plant-derived nanocarriers for targeted drug delivery in cancer therapy. Phytomedicine Plus. 5, 100828 (2025). https://doi.org/10.1016/j.phyplu.2025.100828
30. Abedi-Gaballu, F., Dehghan, G., Ghaffari, M., Yekta, R., Abbaspour-Ravasjani, S., Baradaran, B., Dolatabadi, J.E.N., Hamblin, M.R.: PAMAM dendrimers as efficient drug and gene delivery nanosystems for cancer therapy. Appl. Mater. Today. 12, 177–190 (2018). https://doi.org/10.1016/j.apmt.2018.05.002
31. Alamos-Musre, S., Beltrán-Chacana, D., Moyano, J., Márquez-Miranda, V., Duarte, Y., Miranda-Rojas, S., Olguín, Y., Fuentes, J.A., González-Nilo, D., Otero, M.C.: From Structure to Function: The Promise of PAMAM Dendrimers in Biomedical Applications. Pharmaceutics. 17, 927 (2025). https://doi.org/10.3390/pharmaceutics17070927
32. Pérez-Ferreiro, M., M. Abelairas, A., Criado, A., Gómez, I.J., Mosquera, J.: Dendrimers: Exploring Their Wide Structural Variety and Applications. Polymers. 15, 4369 (2023). https://doi.org/10.3390/polym15224369
33. Yanar, F., Carugo, D., Zhang, X.: Hybrid Nanoplatforms Comprising Organic Nanocompartments Encapsulating Inorganic Nanoparticles for Enhanced Drug Delivery and Bioimaging Applications. Molecules. 28, 5694 (2023). https://doi.org/10.3390/molecules28155694
34. Sinitsyna, V.V., Vetcher, A.A.: Nucleic Acid Aptamers in Nanotechnology. Biomedicines. 10, 1079 (2022). https://doi.org/10.3390/biomedicines10051079
35. Ashrafizadeh, M., Delfi, M., Zarrabi, A., Bigham, A., Sharifi, E., Rabiee, N., Paiva-Santos, A.C., Kumar, A.P., Tan, S.C., Hushmandi, K., Ren, J., Zare, E.N., Makvandi, P.: Stimuli-responsive liposomal nanoformulations in cancer therapy: Pre-clinical & clinical approaches. J. Controlled Release. 351, 50–80 (2022). https://doi.org/10.1016/j.jconrel.2022.08.001
36. Yan, Y., Yuan, J., Luo, X., Yu, X., Lu, J., Hou, W., He, X., Zhang, L., Cao, J., Wang, H.: microRNA-140 Regulates PDGFRα and Is Involved in Adipocyte Differentiation. Front. Mol. Biosci. 9, (2022). https://doi.org/10.3389/fmolb.2022.907148
37. Batchuluun, B., Pinkosky, S.L., Steinberg, G.R.: Lipogenesis inhibitors: therapeutic opportunities and challenges. Nat. Rev. Drug Discov. 21, 283–305 (2022). https://doi.org/10.1038/s41573-021-00367-2
38. Guilherme, A., Rowland, L.A., Wetoska, N., Tsagkaraki, E., Santos, K.B., Bedard, A.H., Henriques, F., Kelly, M., Munroe, S., Pedersen, D.J., Ilkayeva, O.R., Koves, T.R., Tauer, L., Pan, M., Han, X., Kim, J.K., Newgard, C.B., Muoio, D.M., Czech, M.P.: Acetyl-CoA carboxylase 1 is a suppressor of the adipocyte thermogenic program. Cell Rep. 42, 112488 (2023). https://doi.org/10.1016/j.celrep.2023.112488
39. Kononova, Y.A., Tuchina, T.P., Babenko, A.Y.: Brown and Beige Adipose Tissue: One or Different Targets for Treatment of Obesity and Obesity-Related Metabolic Disorders? Int. J. Mol. Sci. 25, 13295 (2024). https://doi.org/10.3390/ijms252413295
40. Jiang, N., Yang, M., Han, Y., Zhao, H., Sun, L.: PRDM16 Regulating Adipocyte Transformation and Thermogenesis: A Promising Therapeutic Target for Obesity and Diabetes. Front. Pharmacol. 13, (2022). https://doi.org/10.3389/fphar.2022.870250
41. AL-Suhaimi, E.A., Shehzad, A.: Leptin, resistin and visfatin: the missing link between endocrine metabolic disorders and immunity. Eur. J. Med. Res. 18, 12 (2013). https://doi.org/10.1186/2047-783X-18-12
42. Asgari, R., Caceres-Valdiviezo, M., Wu, S., Hamel, L., Humber, B.E., Agarwal, S.M., Fletcher, P.J., Fulton, S., Hahn, M.K., Pereira, S.: Regulation of energy balance by leptin as an adiposity signal and modulator of the reward system. Mol. Metab. 91, 102078 (2025). https://doi.org/10.1016/j.molmet.2024.102078
43. Wang, T., Wang, J., Hu, X., Huang, X.-J., Chen, G.-X.: Current understanding of glucose transporter 4 expression and functional mechanisms. World J. Biol. Chem. 11, 76–98 (2020). https://doi.org/10.4331/wjbc.v11.i3.76
44. Spolitu, S., Dai, W., Zadroga, J.A., Ozcan, L.: PCSK9 and Lipid Metabolism. Curr. Opin. Lipidol. 30, 186–191 (2019). https://doi.org/10.1097/MOL.0000000000000601
45. Kara, A., Ongoren, B., Anaya, B.J., Lalatsa, A., Serrano, D.R.: Continuous manufacturing of nanomedicines using 3D-printed microfluidic devices. Appl. Mater. Today. 43, 102672 (2025). https://doi.org/10.1016/j.apmt.2025.102672
46. Desai, N., Rana, D., Patel, M., Bajwa, N., Prasad, R., Vora, L.K.: Nanoparticle Therapeutics in Clinical Perspective: Classification, Marketed Products, and Regulatory Landscape. Small Weinh. Bergstr. Ger. 21, 2502315 (2025). https://doi.org/10.1002/smll.202502315

47. Steenackers, N., Toumazia, J., Deleus, E., Mertens, A., Lannoo, M., Pazmino, S., van Laar, A.D.E., Van der Schueren, B., Vangoitsenhoven, R.: Pharmacotherapy for obesity: are we ready to select, tailor and combine pharmacotherapy to achieve more ambitious goals? Front. Endocrinol. 16, (2025). https://doi.org/10.3389/fendo.2025.1569468
48. Phares, S., Trusheim, M., Emond, S.K., Pearson, S.D.: Managing the challenges of paying for gene therapy: strategies for market action and policy reform in the United States. J. Comp. Eff. Res. 13, e240118. https://doi.org/10.57264/cer-2024-0118
49. Swetha, K., Kotla, N.G., Tunki, L., Jayaraj, A., Bhargava, S.K., Hu, H., Bonam, S.R., Kurapati, R.: Recent Advances in the Lipid Nanoparticle-Mediated Delivery of mRNA Vaccines. Vaccines. 11, 658 (2023). https://doi.org/10.3390/vaccines11030658
50. Stewart, W., Hu, B., Li, F., Huang, J., Liu, Z., Zhang, C., Tang, M., Zhang, X.-Q., Xu, X.: A combinatorial siRNA and mRNA approach for obesity treatment using targeting lipid nanoparticles. J. Controlled Release. 383, 113857 (2025). https://doi.org/10.1016/j.jconrel.2025.113857
51. Busetto, L., Sbraccia, P., Vettor, R.: Obesity management: at the forefront against disease stigma and therapeutic inertia. Eat. Weight Disord. - Stud. Anorex. Bulim. Obes. 27, 761–768 (2022). https://doi.org/10.1007/s40519-021-01217-1

CITE AS: Mukisa Ian Mugaiga (2025). Nanoparticle Based Gene Therapy for Obesity and Metabolic Syndrome. IDOSR JOURNAL OF SCIENTIFIC RESEARCH 10(2):112-118. https://doi.org/10.59298/IDOSRJSR/2024/10.2.112118